PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali
MP3•Episode home
Manage episode 253961330 series 2547109
Content provided by Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries. KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7 Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
…
continue reading
383 episodes
MP3•Episode home
Manage episode 253961330 series 2547109
Content provided by Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries. KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7 Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
…
continue reading
383 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.